Abstract
Summary
Azelnidipine is a dihydropyridine calcium channel blocker.Azelnidipine is L and T calcium channel blocker.Unlike nicardipine, it has a gradual onset and has a long-lasting hypotensive effect, with little increase in heart rate.
LPI (LP Information)' newest research report, the “Azelnidipine API Industry Forecast” looks at past sales and reviews total world Azelnidipine API sales in 2022, providing a comprehensive analysis by region and market sector of projected Azelnidipine API sales for 2023 through 2029. With Azelnidipine API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Azelnidipine API industry.
This Insight Report provides a comprehensive analysis of the global Azelnidipine API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Azelnidipine API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Azelnidipine API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Azelnidipine API and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Azelnidipine API.
The global Azelnidipine API market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Azelnidipine API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Azelnidipine API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Azelnidipine API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Azelnidipine API players cover Honour Lab Limited, Glenmark Pharmaceuticals, Kimia Biosciences Ltd, Zhejiang Guobang Pharmaceutical, SAMOH PHARM. CO., LTD., Ralington Pharma and DONGBANG FTL, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Azelnidipine API market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
≥99.0%
≥98.0%
Segmentation by application
Tablets
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Honour Lab Limited
Glenmark Pharmaceuticals
Kimia Biosciences Ltd
Zhejiang Guobang Pharmaceutical
SAMOH PHARM. CO., LTD.
Ralington Pharma
DONGBANG FTL
Key Questions Addressed in this Report
What is the 10-year outlook for the global Azelnidipine API market?
What factors are driving Azelnidipine API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Azelnidipine API market opportunities vary by end market size?
How does Azelnidipine API break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Azelnidipine API Industry Forecast” looks at past sales and reviews total world Azelnidipine API sales in 2022, providing a comprehensive analysis by region and market sector of projected Azelnidipine API sales for 2023 through 2029. With Azelnidipine API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Azelnidipine API industry.
This Insight Report provides a comprehensive analysis of the global Azelnidipine API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Azelnidipine API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Azelnidipine API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Azelnidipine API and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Azelnidipine API.
The global Azelnidipine API market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Azelnidipine API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Azelnidipine API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Azelnidipine API is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Azelnidipine API players cover Honour Lab Limited, Glenmark Pharmaceuticals, Kimia Biosciences Ltd, Zhejiang Guobang Pharmaceutical, SAMOH PHARM. CO., LTD., Ralington Pharma and DONGBANG FTL, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Azelnidipine API market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
≥99.0%
≥98.0%
Segmentation by application
Tablets
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Honour Lab Limited
Glenmark Pharmaceuticals
Kimia Biosciences Ltd
Zhejiang Guobang Pharmaceutical
SAMOH PHARM. CO., LTD.
Ralington Pharma
DONGBANG FTL
Key Questions Addressed in this Report
What is the 10-year outlook for the global Azelnidipine API market?
What factors are driving Azelnidipine API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Azelnidipine API market opportunities vary by end market size?
How does Azelnidipine API break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Azelnidipine API Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Azelnidipine API by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Azelnidipine API by Country/Region, 2018, 2022 & 2029
2.2 Azelnidipine API Segment by Type
2.2.1 ≥99.0%
2.2.2 ≥98.0%
2.3 Azelnidipine API Sales by Type
2.3.1 Global Azelnidipine API Sales Market Share by Type (2018-2023)
2.3.2 Global Azelnidipine API Revenue and Market Share by Type (2018-2023)
2.3.3 Global Azelnidipine API Sale Price by Type (2018-2023)
2.4 Azelnidipine API Segment by Application
2.4.1 Tablets
2.4.2 Others
2.5 Azelnidipine API Sales by Application
2.5.1 Global Azelnidipine API Sale Market Share by Application (2018-2023)
2.5.2 Global Azelnidipine API Revenue and Market Share by Application (2018-2023)
2.5.3 Global Azelnidipine API Sale Price by Application (2018-2023)
3 Global Azelnidipine API by Company
3.1 Global Azelnidipine API Breakdown Data by Company
3.1.1 Global Azelnidipine API Annual Sales by Company (2018-2023)
3.1.2 Global Azelnidipine API Sales Market Share by Company (2018-2023)
3.2 Global Azelnidipine API Annual Revenue by Company (2018-2023)
3.2.1 Global Azelnidipine API Revenue by Company (2018-2023)
3.2.2 Global Azelnidipine API Revenue Market Share by Company (2018-2023)
3.3 Global Azelnidipine API Sale Price by Company
3.4 Key Manufacturers Azelnidipine API Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Azelnidipine API Product Location Distribution
3.4.2 Players Azelnidipine API Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Azelnidipine API by Geographic Region
4.1 World Historic Azelnidipine API Market Size by Geographic Region (2018-2023)
4.1.1 Global Azelnidipine API Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Azelnidipine API Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Azelnidipine API Market Size by Country/Region (2018-2023)
4.2.1 Global Azelnidipine API Annual Sales by Country/Region (2018-2023)
4.2.2 Global Azelnidipine API Annual Revenue by Country/Region (2018-2023)
4.3 Americas Azelnidipine API Sales Growth
4.4 APAC Azelnidipine API Sales Growth
4.5 Europe Azelnidipine API Sales Growth
4.6 Middle East & Africa Azelnidipine API Sales Growth
5 Americas
5.1 Americas Azelnidipine API Sales by Country
5.1.1 Americas Azelnidipine API Sales by Country (2018-2023)
5.1.2 Americas Azelnidipine API Revenue by Country (2018-2023)
5.2 Americas Azelnidipine API Sales by Type
5.3 Americas Azelnidipine API Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Azelnidipine API Sales by Region
6.1.1 APAC Azelnidipine API Sales by Region (2018-2023)
6.1.2 APAC Azelnidipine API Revenue by Region (2018-2023)
6.2 APAC Azelnidipine API Sales by Type
6.3 APAC Azelnidipine API Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Azelnidipine API by Country
7.1.1 Europe Azelnidipine API Sales by Country (2018-2023)
7.1.2 Europe Azelnidipine API Revenue by Country (2018-2023)
7.2 Europe Azelnidipine API Sales by Type
7.3 Europe Azelnidipine API Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Azelnidipine API by Country
8.1.1 Middle East & Africa Azelnidipine API Sales by Country (2018-2023)
8.1.2 Middle East & Africa Azelnidipine API Revenue by Country (2018-2023)
8.2 Middle East & Africa Azelnidipine API Sales by Type
8.3 Middle East & Africa Azelnidipine API Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Azelnidipine API
10.3 Manufacturing Process Analysis of Azelnidipine API
10.4 Industry Chain Structure of Azelnidipine API
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Azelnidipine API Distributors
11.3 Azelnidipine API Customer
12 World Forecast Review for Azelnidipine API by Geographic Region
12.1 Global Azelnidipine API Market Size Forecast by Region
12.1.1 Global Azelnidipine API Forecast by Region (2024-2029)
12.1.2 Global Azelnidipine API Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Azelnidipine API Forecast by Type
12.7 Global Azelnidipine API Forecast by Application
13 Key Players Analysis
13.1 Honour Lab Limited
13.1.1 Honour Lab Limited Company Information
13.1.2 Honour Lab Limited Azelnidipine API Product Portfolios and Specifications
13.1.3 Honour Lab Limited Azelnidipine API Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Honour Lab Limited Main Business Overview
13.1.5 Honour Lab Limited Latest Developments
13.2 Glenmark Pharmaceuticals
13.2.1 Glenmark Pharmaceuticals Company Information
13.2.2 Glenmark Pharmaceuticals Azelnidipine API Product Portfolios and Specifications
13.2.3 Glenmark Pharmaceuticals Azelnidipine API Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Glenmark Pharmaceuticals Main Business Overview
13.2.5 Glenmark Pharmaceuticals Latest Developments
13.3 Kimia Biosciences Ltd
13.3.1 Kimia Biosciences Ltd Company Information
13.3.2 Kimia Biosciences Ltd Azelnidipine API Product Portfolios and Specifications
13.3.3 Kimia Biosciences Ltd Azelnidipine API Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Kimia Biosciences Ltd Main Business Overview
13.3.5 Kimia Biosciences Ltd Latest Developments
13.4 Zhejiang Guobang Pharmaceutical
13.4.1 Zhejiang Guobang Pharmaceutical Company Information
13.4.2 Zhejiang Guobang Pharmaceutical Azelnidipine API Product Portfolios and Specifications
13.4.3 Zhejiang Guobang Pharmaceutical Azelnidipine API Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Zhejiang Guobang Pharmaceutical Main Business Overview
13.4.5 Zhejiang Guobang Pharmaceutical Latest Developments
13.5 SAMOH PHARM. CO., LTD.
13.5.1 SAMOH PHARM. CO., LTD. Company Information
13.5.2 SAMOH PHARM. CO., LTD. Azelnidipine API Product Portfolios and Specifications
13.5.3 SAMOH PHARM. CO., LTD. Azelnidipine API Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 SAMOH PHARM. CO., LTD. Main Business Overview
13.5.5 SAMOH PHARM. CO., LTD. Latest Developments
13.6 Ralington Pharma
13.6.1 Ralington Pharma Company Information
13.6.2 Ralington Pharma Azelnidipine API Product Portfolios and Specifications
13.6.3 Ralington Pharma Azelnidipine API Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Ralington Pharma Main Business Overview
13.6.5 Ralington Pharma Latest Developments
13.7 DONGBANG FTL
13.7.1 DONGBANG FTL Company Information
13.7.2 DONGBANG FTL Azelnidipine API Product Portfolios and Specifications
13.7.3 DONGBANG FTL Azelnidipine API Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 DONGBANG FTL Main Business Overview
13.7.5 DONGBANG FTL Latest Developments
14 Research Findings and Conclusion